Aurobindo Pharma

    AUROPHARMA
    Pharma
    ₹1679.80
    price as of 11/9/2026, 5:27:57 pm

    Market cap ₹96,652 Cr

    P/E
    26.22
    Day range
    ₹1,655.50 – ₹1,681.40
    52-week range
    ₹1,066.80 – ₹1,717.00
    Volume
    4.94 L
    Open
    ₹1,666.70
    Prev close
    ₹1,668.40
    Promoters pledged 16.7% of their shares
    52-week range, adjusted for splits and bonuses
    ₹1,048₹1,717
    10 Sept 202531 Aug 2026
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 550

    Price history

    6M change +28.74%RSI (14) 57.0 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 50.4% today vs 48.1% average · BSE close ₹1,675.45

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹1,200₹1,350₹1,500₹1,650₹1,8000%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Long build-up
    Near-month future
    ₹1,678.2
    Change
    +0.45%
    Basis over spot
    −₹1.58
    Futures OI (shares)
    1.14 Cr
    OI change
    +0.57%
    Put-call ratio
    0.42
    Max pain
    ₹1,640
    Resistance (call OI)
    ₹1,700
    Support (put OI)
    ₹1,660
    Lot size
    550

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    140014601500154015801620166017001740178018201860192003.5 L7.0 L10.5 L14.0 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    24.7
    EPS (TTM)
    ₹64.00
    Price / Book
    2.60
    ROE (FY26)
    9.9%
    ROCE (latest year)
    13%
    Dividend yield
    0.00%
    Net margin (TTM)
    10.6%
    Current ratio
    1.81
    Debt / Equity
    0.03
    Revenue growth (5y)
    6.3%
    EPS growth (5y)
    -7.9%

    Moving averages (NSE)

    Simple moving averages of the NSE price, and where the last price sits against each
    5-day10-day20-day50-day100-day300-day
    ₹1,662.78Price above₹1,655.4Price above₹1,644.93Price above₹1,601.11Price above₹1,529.01Price above₹1,373.08Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +10.6%
    Profit 3Y CAGR
    +22.0%
    Revenue YoY (Jun 2026)
    +16.3%
    Profit YoY (Jun 2026)
    +25.2%
    Operating margin
    21.0%
    Net margin
    11.3%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr2.5K Cr5.0K Cr7.5K Cr10.0K Cr0%6%12%18%24%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-6.0K Cr-3.0K Cr0 Cr3.0K Cr6.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%7%14%21%28%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr9.5K Cr19.0K Cr28.5K Cr38.0K Cr0.0x0.1x0.3x0.5x0.6x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales7,2197,3527,5807,5677,7967,9798,3827,8688,2868,6468,8539,150
    Expenses5,8465,7535,9205,9496,2306,4016,6226,2656,6086,8737,1037,271
    Operating Profit1,3731,5991,6601,6181,5661,5781,7601,6031,6781,7731,7501,880
    OPM %19%22%22%21%20%20%21%20%20%21%20%21%
    Other Income18816314221136159135107122123117224
    Interest68768911111311811598959398102
    Depreciation418423354404382419444406429465479487
    Profit before tax1,0761,2621,2301,3241,2071,2001,3351,2071,2761,3391,2911,515
    Tax %30%26%26%31%32%30%32%32%34%32%29%32%
    Net Profit7529409079188178469038248489109211,032
    EPS in Rs₹12.92₹15.98₹15.51₹15.69₹14.07₹14.56₹15.56₹14.20₹14.61₹15.67₹15.86₹17.95

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 2.57 times its book value
    • The company has delivered a poor sales growth of 6.32% over past five years.
    • Company has a low return on equity of 10.8% over last 3 years.
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    +9%
    5 Years
    +6%
    3 Years
    +11%
    TTM
    +9%

    Compounded Profit Growth

    10 Years
    +6%
    5 Years
    +1%
    3 Years
    +23%
    TTM
    +11%

    Stock Price CAGR

    10 Years
    +8%
    5 Years
    +18%
    3 Years
    +24%
    1 Year
    +51%

    Return on Equity

    10 Years
    +14%
    5 Years
    +10%
    3 Years
    +11%
    Last Year
    +10%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter51.82%51.82%51.82%51.88%+0.06 pp
    FII14.21%13.95%15.24%16.38%+1.14 pp
    DII27.60%27.66%25.82%25.05%-0.77 pp
    Government0.00%0.03%0.05%0.05%0.00 pp
    Public6.37%6.55%7.08%6.63%-0.45 pp

    Filed with NSE for Jun 2026: promoters 51.88%, public 48.12% · XBRL filing

    Analysts & fund holdings

    72%
    72% recommend buy
    25 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E26.2 vs 46.4
    Sector P/B5.84
    Beta0.91

    Who holds the shares, quarter by quarter

    Mutual funds 16.71% (-1.08 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters51.9%
    • Foreign institutions16.4%
    • Mutual funds16.7%
    • Insurance5.0%
    • Other domestic institutions3.4%
    • Retail5.0%
    • Others1.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Mid Cap Fund2.46%2.12%+0.03 pp
    Quant ELSS Tax Saver Fund1.22%8.49%+0.50 pp
    Quant Mid Cap Fund0.90%10.45%+0.04 pp
    SBI Large & Midcap Fund0.86%1.91%-0.16 pp
    Quant Multi Cap Fund0.78%9.46%+0.80 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • buyback
      Not available — not reported in this filing

      Buy Back

      17 Apr 2026
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      8 Aug 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      26 Aug 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      30 Jul 2024
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      20 Feb 2024
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      20 Nov 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Aug 2023
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      17 Feb 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Jul 2022
      ex-date
    • dividend
      ₹4.50

      Interim Dividend - Rs 4.50 Per Share

      6 Jun 2022
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      18 Feb 2022
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      17 Nov 2021
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      27 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Aug 2021
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      22 Feb 2021
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      23 Nov 2020
      ex-date
    • dividend
      ₹1.25

      Annual General Meeting/Interim Dividend - Rs 1.25 Per Share

      21 Aug 2020
      ex-date
    • dividend
      ₹1.75

      Interim Dividend - Rs 1.75 Per Share

      17 Feb 2020
      ex-date
    • dividend
      ₹1.25

      Interim Dividend - Rs 1.25 Per Share

      21 Nov 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Aug 2019
      ex-date

    Insider trades

    Last 12 months, market trades
    No market trades
    0 buys · ₹0
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released1,16,35,862₹1267 Cr1 Apr 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge1,67,00,000₹1759 Cr28 Mar 2024
    PAVANKUMAR PS
    Employees/Designated Employees · Market Sale
    		Sell1,000₹10.2 L5 Mar 2024
    CHANDRASEKHAR REDDY KANDATI
    Employees/Designated Employees · Market Sale
    		Sell2,000₹20.9 L1 Mar 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released1,00,50,000₹1049 Cr26 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Revokation of Pledge
    		Pledge released23,00,000₹240 Cr26 Feb 2024
    ROOPAK SAWHNEY
    Employees/Designated Employees · Market Sale
    		Sell3,880₹39.2 L16 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge1,34,00,000₹1335 Cr16 Feb 2024
    K BHARATHI
    Other · Market Sale
    		Sell35,000₹3.6 Cr16 Feb 2024
    GITA RAO
    Employees/Designated Employees · Market Sale
    		Sell1,300₹12.8 L16 Feb 2024
    S BALA SUBRAMANYAM REDDY
    Employees/Designated Employees · Market Sale
    		Sell2,000₹20.5 L16 Feb 2024
    RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)
    Promoter Group · Pledge Creation
    		Pledge2,50,000₹28.0 Cr19 Jan 2024

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor / analyst meet scheduled on 22.09.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor / analyst meet scheduled on 21.09.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor / analyst meet scheduled on 17.09.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of investor / analyst meet scheduled on 18.09.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Investor / analyst meet scheduled on 17.09.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Submission of notice published in newspapers.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited' by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

    Submission of Press Release.

    Company Update
    Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company

    Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of Voting Results and Scrutinizer's Report of 39th AGM of the Company held on August 27, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Participation in Investor/ Analyst meet held on September 1-2, 2026 in Hong Kong

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Investor/ Analyst meet scheduled on September 1, 2026.

    Company Update
    Completion Of US FDA Inspection At Lannett Company LLC, A Wholly Owned Subsidiary Of Aurobindo Pharma USA, Inc.

    Intimation of completion of US FDA inspection at Lannett Company LLC., a wholly owned subsidiary of Aurobindo Pharma, USA Inc.

    Company Update
    Completion Of US FDA Inspection At Auro Peptides Ltd, A Subsidiary/Business Arm Of The Company.

    Intimation of completion of US FDA inspection at Auro Peptides Limited, a subsidiary of the Company.

    Filed with BSE (scrip 524804); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Final order

      Final Order in the matter of Aurobindo Pharma Ltd [SAT Appeal No.: 23/2021 & Misc. App. No. 559/2020]

      4 Aug 2020
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Mr. PV Ramprasad Reddy, Mrs. P. Suneela Rani, Mr. Kambam P Reddy, Trident Chemphar Ltd., Veritaz Health Care Ltd., Top Class Capital Markets Pvt. Ltd. and Aurobindo Pharma Ltd. in the matter of Aurobindo Pharma Ltd. [SAT Appeal No.: 559/2019] [SAT Appeal No.: 31/2020 & Misc. App. No. 38/2020]

      23 Sept 2019
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Sumanth Kumar Reddy Mettu (in the matter of Aurobindo Pharma Ltd)

      22 May 2017
      Read on SEBI
    • Adjudication order

      Adjudication order against Brijwasi Securities Private Limited in the matter of Aurobindo Pharma Limited

      27 Aug 2009
      Read on SEBI
    • Order

      Order in the matter of Aurobindo Pharma Limited

      13 Oct 2008
      Read on SEBI

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Feb 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.